KR100783863B1 - 7-아릴-3,9-디아자바이사이클로(3.3.1)논-6-엔 유도체 및고혈압, 심혈관 질환 또는 신장 질환의 치료에서 레닌저해물질로써 이들의 용도 - Google Patents

7-아릴-3,9-디아자바이사이클로(3.3.1)논-6-엔 유도체 및고혈압, 심혈관 질환 또는 신장 질환의 치료에서 레닌저해물질로써 이들의 용도 Download PDF

Info

Publication number
KR100783863B1
KR100783863B1 KR1020047016845A KR20047016845A KR100783863B1 KR 100783863 B1 KR100783863 B1 KR 100783863B1 KR 1020047016845 A KR1020047016845 A KR 1020047016845A KR 20047016845 A KR20047016845 A KR 20047016845A KR 100783863 B1 KR100783863 B1 KR 100783863B1
Authority
KR
South Korea
Prior art keywords
phenyl
diazabicyclo
propyl
ene
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047016845A
Other languages
English (en)
Korean (ko)
Other versions
KR20040101546A (ko
Inventor
올리비에르 베젠콘
다니엘 부르
왈터 피스칠리
루보스 레멘
실비아 리차드-빌드스테인
한스-피터 웨버
토마스 웰러
Original Assignee
액테리온 파마슈티칼 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29286070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100783863(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 액테리온 파마슈티칼 리미티드 filed Critical 액테리온 파마슈티칼 리미티드
Publication of KR20040101546A publication Critical patent/KR20040101546A/ko
Application granted granted Critical
Publication of KR100783863B1 publication Critical patent/KR100783863B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020047016845A 2002-04-29 2003-04-08 7-아릴-3,9-디아자바이사이클로(3.3.1)논-6-엔 유도체 및고혈압, 심혈관 질환 또는 신장 질환의 치료에서 레닌저해물질로써 이들의 용도 Expired - Fee Related KR100783863B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP0204705 2002-04-29
EPPCT/EP02/04705 2002-04-29
PCT/EP2003/003721 WO2003093267A1 (en) 2002-04-29 2003-04-08 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases

Publications (2)

Publication Number Publication Date
KR20040101546A KR20040101546A (ko) 2004-12-02
KR100783863B1 true KR100783863B1 (ko) 2007-12-10

Family

ID=29286070

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047016845A Expired - Fee Related KR100783863B1 (ko) 2002-04-29 2003-04-08 7-아릴-3,9-디아자바이사이클로(3.3.1)논-6-엔 유도체 및고혈압, 심혈관 질환 또는 신장 질환의 치료에서 레닌저해물질로써 이들의 용도

Country Status (26)

Country Link
US (2) US7427613B2 (https=)
EP (1) EP1501830B1 (https=)
JP (1) JP4041123B2 (https=)
KR (1) KR100783863B1 (https=)
CN (1) CN1649870A (https=)
AT (1) ATE527261T1 (https=)
AU (1) AU2003233963B2 (https=)
BR (1) BR0309498A (https=)
CA (1) CA2483241C (https=)
CL (1) CL2003002042A1 (https=)
CO (1) CO5631443A2 (https=)
EC (1) ECSP045378A (https=)
ES (1) ES2372931T3 (https=)
HR (1) HRP20041132A2 (https=)
IL (1) IL164767A0 (https=)
IS (1) IS7545A (https=)
MA (1) MA27305A1 (https=)
MX (1) MXPA04010608A (https=)
NO (1) NO20045042L (https=)
NZ (1) NZ536750A (https=)
PL (1) PL372141A1 (https=)
RU (1) RU2343153C2 (https=)
TW (1) TW200514786A (https=)
UA (1) UA80821C2 (https=)
WO (1) WO2003093267A1 (https=)
ZA (1) ZA200408283B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1780836A (zh) * 2003-04-28 2006-05-31 埃科特莱茵药品有限公司 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物
JP2006524657A (ja) * 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド 新規トロパン誘導体
KR20060008937A (ko) * 2003-04-30 2006-01-27 액테리온 파마슈티칼 리미티드 레닌 억제제로서 3-위치에 헤테로원자를 갖는9-아자비사이클로[3.3.1]논-6-엔 유도체
KR20060006069A (ko) * 2003-04-30 2006-01-18 액테리온 파마슈티칼 리미티드 아자비사이클로노넨 유도체
EP1622564A2 (en) * 2003-05-02 2006-02-08 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives
WO2004105762A1 (en) * 2003-05-30 2004-12-09 Actelion Pharmaceuticals Ltd Medical use of diazabicyclononene derivatives as inhibitors of parasite aspartic proteases
CA2540543A1 (en) * 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd Tetrahydropyridine derivatives
WO2005040165A1 (en) * 2003-10-13 2005-05-06 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
CA2540817A1 (en) * 2003-10-23 2005-05-06 Olivier Bezencon Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
AU2004295091A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
AU2004295092A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd. Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
WO2006021399A2 (en) * 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Azabicyclononene derivatives as renin inhibitors
WO2006021403A1 (en) * 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicyclononene derivatives
WO2006021401A2 (en) * 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicylononene derivatives
ATE462703T1 (de) * 2004-08-25 2010-04-15 Actelion Pharmaceuticals Ltd Bicyclononen-derivate als renin-inhibitoren
AR052263A1 (es) * 2004-12-08 2007-03-07 Actelion Pharmaceuticals Ltd Derivado de diazabiciclononeno
WO2006063610A1 (en) * 2004-12-17 2006-06-22 Actelion Pharmaceuticals Ltd Heteroaryl substituted diazabicyclononene derivatives
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
KR100938364B1 (ko) * 2005-01-28 2010-01-22 액테리온 파마슈티칼 리미티드 고혈압 치료를 위한, 레닌의 억제제로서의 7-｛4-[2-(2,6-디클로로-4-메틸페녹시)에톡시]페닐｝-3,9-디아자비시클로[3.3.1]논-6-엔-6-카르복실산 시클로프로필-(2,3-디메틸벤질)아미드
GEP20115206B (en) * 2005-05-27 2011-04-26 Actelion Pharmaceuticals Ltd Novel piperidine carboxylic acid amide derivatives
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
BRPI0620736A2 (pt) 2005-12-30 2011-12-20 Novartis Ag compostos orgánicos
NZ570828A (en) 2006-02-02 2011-07-29 Actelion Pharmaceuticals Ltd Secondary amines as renin inhibitors
CN101395149A (zh) * 2006-03-08 2009-03-25 埃科特莱茵药品有限公司 新颖胺类
AU2008253519A1 (en) 2007-05-24 2008-11-27 Merck Frosst Canada Ltd Novel case of renin inhibitors
SG182223A1 (en) 2007-06-25 2012-07-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
AU2008288648A1 (en) 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Renin inhibitors
KR101403311B1 (ko) 2008-05-05 2014-06-05 액테리온 파마슈티칼 리미티드 레닌 억제제로서의 3,4-치환된 피페리딘 유도체
CN109721613B (zh) * 2017-10-27 2021-07-30 四川科伦博泰生物医药股份有限公司 含季铵离子的大环酰胺化合物及其药物组合物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509161A (en) 1967-07-10 1970-04-28 Boehringer & Soehne Gmbh 3-phenyl-granatene-(2)-derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
US5268361A (en) * 1991-06-07 1993-12-07 Sri International Hydroxyazido derivatives and related compounds as renin inhibitors
US5374719A (en) * 1993-06-04 1994-12-20 Eli Lilly And Company Process for converting loracarbef dihydrate to loracarbef monohydrate
TR199800409T1 (xx) * 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
EP0966464B1 (en) 1997-03-03 2003-05-28 Basilea Pharmaceutica AG Substituted 2,4-diaminopyrimidines
US20060223795A1 (en) * 2003-05-02 2006-10-05 Oliver Bezencon Novel diazabicyclononene derivatives
AU2004295091A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509161A (en) 1967-07-10 1970-04-28 Boehringer & Soehne Gmbh 3-phenyl-granatene-(2)-derivatives

Also Published As

Publication number Publication date
AU2003233963A1 (en) 2003-11-17
EP1501830B1 (en) 2011-10-05
ATE527261T1 (de) 2011-10-15
CA2483241C (en) 2011-05-31
ECSP045378A (es) 2004-11-26
IS7545A (is) 2004-11-22
MXPA04010608A (es) 2004-12-13
BR0309498A (pt) 2005-02-15
ZA200408283B (en) 2006-05-31
CL2003002042A1 (es) 2005-02-04
RU2343153C2 (ru) 2009-01-10
AU2003233963B2 (en) 2008-09-11
JP4041123B2 (ja) 2008-01-30
EP1501830A1 (en) 2005-02-02
PL372141A1 (en) 2005-07-11
ES2372931T3 (es) 2012-01-27
WO2003093267A1 (en) 2003-11-13
US20080312242A1 (en) 2008-12-18
TW200514786A (en) 2005-05-01
CN1649870A (zh) 2005-08-03
CO5631443A2 (es) 2006-04-28
UA80821C2 (en) 2007-11-12
NO20045042L (no) 2004-11-19
HRP20041132A2 (en) 2006-07-31
RU2004134320A (ru) 2005-08-27
US20050176700A1 (en) 2005-08-11
MA27305A1 (fr) 2005-05-02
IL164767A0 (en) 2005-12-18
KR20040101546A (ko) 2004-12-02
NZ536750A (en) 2007-02-23
CA2483241A1 (en) 2003-11-13
US7427613B2 (en) 2008-09-23
JP2005527602A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
KR100783863B1 (ko) 7-아릴-3,9-디아자바이사이클로(3.3.1)논-6-엔 유도체 및고혈압, 심혈관 질환 또는 신장 질환의 치료에서 레닌저해물질로써 이들의 용도
US20060009497A1 (en) Novel tetrahydropyridine derivatives as renin inhibitors
EA020816B1 (ru) Ингибиторы вирусов flaviviridae
JP2006525259A (ja) 新規ジアザビシクロノネン誘導体
JP2006524655A (ja) ３−位にヘテロ原子を有する新規９−アザビシクロノネン誘導体
JP2007508260A (ja) 新規なテトラヒドロピリジン誘導体
JP2006524656A (ja) 新規ジアザビシクロノネンおよびテトラヒドロピリジン誘導体
JP2006524654A (ja) 新規アザビシクロノネン誘導体
AU2004295092A1 (en) Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
JP2006524657A (ja) 新規トロパン誘導体
AU2004283821A1 (en) Diazabicyclononene derivatives and their use as renin inhibitors
JP2007509099A (ja) 新規ジアザビシクロノネンおよび新規極性側鎖を有するテトラヒドロピリジン誘導体
JP2008510755A (ja) ビシクロノネン誘導体
WO2004105762A1 (en) Medical use of diazabicyclononene derivatives as inhibitors of parasite aspartic proteases
AU2004295091A1 (en) Diazabicyclononene derivatives and their use as renin inhibitors
KR20050019759A (ko) 레닌 억제제로서의 신규한 테트라하이드로피리딘 유도체
EP1692132A2 (en) Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20111129

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20121204

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20121204